A Safety and Tolerability Study of ABT-126 in Elderly

Abbott logo

Abbott

Status and phase

Completed
Phase 1

Conditions

Alzheimer's Disease

Treatments

Drug: ABT-126

Study type

Interventional

Funder types

Industry

Identifiers

NCT00867399
M10-717

Details and patient eligibility

About

The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.

Enrollment

30 patients

Sex

All

Ages

65+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male or female subjects 65 years or greater.
  • Has a MMSE score of 27 or higher.

Exclusion criteria

  • History of dementia including by not limited to Alzheimer's disease, Parkinson's disease and mult-infarct dementia.
  • History of any significant neurological disease.
  • Has an estimated creatinine clearance < 30 mL/min

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

Double Blind

30 participants in 2 patient groups

20mg of ABT-126 QD
Active Comparator group
Description:
20 mg of ABT-126 QD for 10 days
Treatment:
Drug: ABT-126
30mg and 45mg ABT-126 QD
Active Comparator group
Description:
30 mg and 45mg of ABT-126 QD for 21 days
Treatment:
Drug: ABT-126

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems